NASDAQ:GANX
Gain Therapeutics, Inc.
Gain Therapeutics, Inc. reported net income of −$20.2M in fiscal 2025. The diluted share count rose 44.1%.Summary generated from Gain Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 26, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−155.7%
Debt / equity0.02
Free cash flown/a
FCF marginn/a
Share count change+44.1%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | n/a | n/a |
| Operating income | −14 | −18 | −22 | −20 | −19 |
| Net income | −14 | −18 | −22 | −20 | −20 |
| Free cash flow | −12 | −15 | −19 | −19 | n/a |
Recent filings
- 8-KOther events
Oct 1, 2026 - 8-KDirector or officer change
Sep 28, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 11, 2026 - 8-KResults of operations and financial condition
Aug 11, 2026 - 4Insider transaction report
Jul 17, 2026 - 4Insider transaction report
Jul 17, 2026 - 8-KOther events
Jul 16, 2026 - 8-KOther events
Jun 29, 2026